

## PHARMACY POLICY STATEMENT

### Marketplace

<b>DRUG NAME</b>	<b>Enspryng (satralizumab-mwge)</b>
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Enspryng is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of

DATE	ACTION/DESCRIPTION
10/16/2020	